OPRX OptimizeRx Corp

OptimizeRx Sets Third Quarter Fiscal 2021 Conference Call for Tuesday, November 9 at 4:30 p.m. ET

OptimizeRx Sets Third Quarter Fiscal 2021 Conference Call for Tuesday, November 9 at 4:30 p.m. ET

ROCHESTER, Mich., Oct. 27, 2021 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Tuesday, November 9, 2021, at  4:30 p.m. Eastern Time to discuss its results for the third quarter, ended September 30, 2021. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question and answer period.

Conference Call Information:

Date:Tuesday, November 9, 2021
Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Webcast:
Toll Free:855-327-6837 
International:631-891-4304 
Conference ID:10016809

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at .  

About OptimizeRx

OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through a proprietary point-of-care network, connectivity is facilitated via its integrated Therapy Initiation and Persistence Platform. This powerful digital healthcare solutions platform is transforming market and patient access with the life sciences market by unlocking:

  • AI-directed, real-time HCP marketing to raise awareness of treatment benefits to give patients a timely start on therapy
  • Streamlined communication and processes around therapy initiation to reduce abandonment through simplified enrollment
  • Personalized, successful adherence programs to help patients stay on their doctor-recommended course of therapy

For more information, follow the company on , or visit .

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact 

Andy D’Silva

SVP Corporate Finance

Media Relations Contact 

Maira Alejandra, Media Relations Manager 

 

Investor Relations Contact

Ashley Robinson

LifeSci Advisors, LLC



EN
27/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases ...

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance -   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan sub...

 PRESS RELEASE

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 202...

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx manageme...

 PRESS RELEASE

OptimizeRx to Participate in the 9th Annual Lake Street Capital Best I...

OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY. To request a meeting or for more details about the Conference, please reac...

 PRESS RELEASE

OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevan...

OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar’s Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (Nasdaq: LAMR), on...

 PRESS RELEASE

OptimizeRx Corporation Announces Leadership Team Advancements to Accel...

OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company’s leadership bench and CEO Steve Silves...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch